SRC kinases Inhibitors
3 drugsAbout SRC kinases
SRC kinases are a family of intracellular non-receptor tyrosine kinases involved in cell growth, differentiation, motility, and adhesion. They act as molecular switches, phosphorylating proteins to trigger downstream signaling cascades.
SRC kinases are attractive drug targets due to their involvement in fundamental cellular functions. Currently, there is no genetic evidence directly linking SRC kinases to specific diseases.
Two FDA-approved drugs, ICLUSIG and OFEV, target SRC kinases as small molecules. These drugs, developed by Takeda and Boehringer Ingelheim, are approved for respiratory diseases and other conditions.
Top SRC kinases Drugs
The competitive landscape includes Takeda and Boehringer Ingelheim, each with an approved drug.
Limited competition suggests opportunity for new entrants, but high barriers to entry due to established players.
SRC kinases Drug Modality Landscape
Modalities
Routes of Administration
SRC kinases is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
SRC kinases Clinical Trials 176 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SRC kinases. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 63 | 42 | 16 | 5 | 72% |
| Phase 2 | 80 | 40 | 24 | 16 | 63% |
| Phase 3 | 24 | 13 | 4 | 7 | 76% |
| Phase 4 | 9 | 7 | 1 | 1 | 88% |
Top Sponsors
By Modality
Top Conditions
SRC kinases Drug Approval Timeline (2011 - 2014)
The first drug targeting SRC kinases was approved in 2012 (ICLUSIG), and the most recent in 2014 (OFEV).
Slow approval rate indicates potential saturation or challenges in developing new SRC kinase inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 87 (20 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SRC kinases. A trial counts if an approved drug acting on SRC kinases is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.